Clinical Trials Logo

Filter by:
NCT ID: NCT05576272 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Start date: May 19, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, open, multicenter phase II/III trial to compare the efficacy and safety of QL1706 and carrilizumab combined with gemcitabine and cisplatin in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT05576168 Completed - Clinical trials for Beta Cell Dysfunction

Related Mechanisms of RBP4 in Glycolipid Metabolism

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

Retinol binding protein 4 ( RBP4 ) is a newly discovered adipokine secreted by adipose tissue, which leads to insulin resistance ( IR ) and participates in the occurrence of T2DM. At present, it's not clear whether RBP4 can cause islet β cell dysfunction. The purpose of this study is to explore the role of serum apo-RBP4 in the pathogenesis of newly diagnosed T2DM patients.

NCT ID: NCT05575986 Recruiting - Trombocitopenia Clinical Trials

Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy

hetrombopag
Start date: October 2022
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of hetrombopag in the treatment of thrombocytopenia after chemotherapy in patients with digestive system malignant tumors

NCT ID: NCT05575973 Not yet recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Start date: October 10, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with rituximab and lenalidomide in the treatment of relapsed and refractory diffuse large B-cell lymphoma (DLBCL).

NCT ID: NCT05575804 Recruiting - Clinical trials for Advanced/ Metastatic Her-2 Positive Breast Cancer

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2 treatment.

NCT ID: NCT05575778 Active, not recruiting - Clinical trials for Critical Limb Ischemia

Peri-operative Foot CT Perfusion in CLI Patients

POP-CLI
Start date: October 1, 2022
Phase:
Study type: Observational

To investigate the clinical value of quantitative analysis of peri-operative foot supply through CT perfusion in patients with critical limb ischemia

NCT ID: NCT05575765 Enrolling by invitation - Clinical trials for Colorectal Neoplasms

Clinical Validation of Multimodal Digestive Endoscopy

Start date: August 14, 2023
Phase:
Study type: Observational

According to the latest global cancer epidemiological data published by the International Agency for Research on Cancer, colorectal cancer (CRC) ranks 3rd in total incidence and 2nd in total mortality among all malignancies worldwide. The prognosis of CRC is directly related to tumor stage. The 5-year survival rate for early CRC can reach 90%, while less than 14% for advanced CRC. Therefore, early diagnosis of CRC is particularly important. Gastrointestinal (GI) endoscopy is an important method in the diagnosis of CRC. Currently, diagnosis of GI endoscopy is mainly based on morphological changes of tumors, while early-stage tumors are difficult to be detected because of the indistinguishable morphology. Studies have shown that the molecular function of cancer cells can be altered in early-stage tumors. The development of a new endoscopic system that can identify early tumor molecular function changes and improve the accuracy of morphological diagnosis will greatly improve the early diagnosis rate of CRC, which is the future direction of GI endoscopic system design and development. The combination of high-definition white light endoscopy, endoscopic cerenkov luminescence imaging (ECLI) and probe-based confocal laser endomicroscopy (pCLE) is ideal for future new GI endoscopy. High-definition white light endoscopy is helpful to quickly find and locate suspected abnormal mucosa; on top of this, ECLI enables molecule-specific functional imaging for accurate identification and determination of GI lesions; and further relies on pCLE for high-precision "cellular-level" lesion images for optical biopsy of lesions. Through the multimodal digestive endoscopy, structural imaging and functional imaging can be accomplished simultaneously, playing the innate advantage of multimodal information fusion diagnosis and facilitating the identification of early-stage tumors. In this clinical trial, twenty patients with colorectal cancer who underwent PET-CT in Xijing Hospital were enrolled. Multimodal digestive endoscopy, combination of high-definition white light endoscopy, ECLI and pCLE, was used to perform for each patient's rectal cancer. ECLI images were compared with PET-CT images, and pCLE images were compared with tumor histopathology, which evaluate the actual imaging effect of multimodal digestive endoscopy in human.

NCT ID: NCT05575752 Active, not recruiting - Cognitive Function Clinical Trials

Acute Health Effects of High Temperature Exposure

Start date: October 23, 2022
Phase: N/A
Study type: Interventional

This is a randomized controlled human exposure crossover study. Investigators aims to assess the acute effects of high temperature exposure and the underlying mechanisms.

NCT ID: NCT05575726 Recruiting - Clinical trials for Chronic Respiratory Disease

Effects of Neutrophil Extracellular Traps and Damage-associated Molecular Pattern Molecules on Long Term Use of Macrolides in Adults With Chronic Respiratory Disease

Start date: August 1, 2021
Phase:
Study type: Observational

The purpose of this study is to investigate the effects of neutrophil extracellular traps and damage-associated molecular pattern molecules on long term use of macrolides in adults with chronic respiratory disease.

NCT ID: NCT05575713 Recruiting - Clinical trials for Major Depressive Disorder

The Effect of Soluble Epoxide Hydrolase (SEH) on Depression

Start date: June 1, 2019
Phase:
Study type: Observational

Depression is the most common mental disease and the second leading cause of chronic disease burden, which is closely related to suicidal behavior. The diagnosis and treatment of depression still lack of effective biological indicators, and about 30% of patients with depression still can not relieve their depressive symptoms after treatment. Previous studies have found that ATP release from astrocytes plays an important role in the occurrence, development and treatment of depression. Epoxy eicosotrienes (eets) are closely related to the function of the nervous system and may be the pathophysiological mechanism of depression. Soluble epoxide hydrolase (SEH) can regulate ATP release by affecting EET degradation, leading to depression like behavior and antidepressant effect, and sEH is closely related to cognitive function of depression.